Office of Research, Endeavour College of Natural Health, Brisbane, Queensland, Australia.
Clinical Trial Unit (Griffith Health), Griffith University Gold Coast, Queensland, Australia.
J Altern Complement Med. 2021 Mar;27(3):198-213. doi: 10.1089/acm.2020.0331. Epub 2020 Dec 8.
Fibromyalgia (FMS) is a complex condition that is characterized by various pain syndromes and fatigue, among other symptoms experienced. Current medical treatment of FMS involves both pharmacological and nonpharmacological approaches, but often with ineffective outcomes. Medicinal cannabis has the potential to be a therapeutic option for patients with FMS due to the positive research in chronic pain management. In addition, it has been found to have fewer adverse effects compared with currently available pain medications. This literature review aims at answering whether medicinal cannabis is reported to be safe and effective for the treatment of pain and symptomology experienced by people with FMS. A systematic review was conducted on human trials utilizing cannabis in FMS. MEDLINE, Embase, CINAHL, AMED, Scopus, and Cochrane CENTRAL were used for databases search, and mesh terms were used for cannabis and FMS. The search was limited to studies conducted from 2000 to 2020. From the 181 citations identified, 10 studies were included after title, abstract, and full text screening occurred. A total of 1136 of patients (intervention = 945, control = 108, crossover = 83) participated in the 10 studies ranging from 9 to 383 patients (mean = 114, median = 36). Of these studies, there were three randomized controlled trials, six observational studies, and one study that compared the management of chronic pain patients with FMS patients. Cannabis was found to be safe and well tolerated in FMS. The main adverse events identified included feeling "high," dizziness/vertigo, dry mouth, cough, red eyes, and drowsiness with no serious adverse events reported. This literature review identified that medical cannabis may be beneficial for some people with FMS. Further studies are required to confirm its efficacy, what type of cannabis is the most effective form to use, and what assessment tools need to be utilized to understand how to quantify clinical outcomes.
纤维肌痛症(FMS)是一种复杂的疾病,其特征是存在各种疼痛综合征和疲劳等症状。目前,纤维肌痛症的治疗包括药物和非药物治疗方法,但通常效果不佳。药用大麻有可能成为纤维肌痛症患者的治疗选择,因为在慢性疼痛管理方面有积极的研究。此外,与现有的止痛药相比,它的副作用更少。本文献综述旨在回答药用大麻是否被报道为安全有效,可用于治疗纤维肌痛症患者的疼痛和症状。 对使用大麻治疗纤维肌痛症的人体试验进行了系统评价。使用 MEDLINE、Embase、CINAHL、AMED、Scopus 和 Cochrane CENTRAL 数据库进行了数据库搜索,并使用大麻和纤维肌痛症的主题词。搜索范围限于 2000 年至 2020 年进行的研究。 在确定的 181 条引文中,经过标题、摘要和全文筛选后,有 10 项研究被纳入。这 10 项研究共纳入 1136 名患者(干预组 945 名,对照组 108 名,交叉组 83 名),患者人数从 9 到 383 名不等(平均 114 名,中位数 36 名)。其中有 3 项随机对照试验、6 项观察性研究和 1 项比较慢性疼痛患者与纤维肌痛症患者管理的研究。研究发现,大麻在纤维肌痛症中是安全且耐受良好的。确定的主要不良事件包括感觉“兴奋”、头晕/眩晕、口干、咳嗽、眼红和嗜睡,但没有报告严重不良事件。 本文献综述确定,医用大麻可能对一些纤维肌痛症患者有益。需要进一步的研究来确认其疗效、最有效的大麻类型以及需要使用哪些评估工具来了解如何量化临床结果。